Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

doi:10.4251/wjgo.v15.i10.1771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2058)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1267

Figures (1-4)

141

Tables (1-5)

130

Sum=1606

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

105

Download

265

Sum=370

Oct 15, 2023 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1771-1783
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1771

Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

Huttakan Navadurong, Thaninee Prasoppokakorn, Nanicha Siriwong, Chonlada Phathong, Nattaya Teeyapun, Suebpong Tanasanvimon, Kessarin Thanapirom, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk, Roongruedee Chaiteerakij

Huttakan Navadurong, Thaninee Prasoppokakorn, Nanicha Siriwong, Chonlada Phathong, Kessarin Thanapirom, Piyawat Komolmit, Sombat Treeprasertsuk, Roongruedee Chaiteerakij, Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Huttakan Navadurong, Thaninee Prasoppokakorn, Nanicha Siriwong, Chonlada Phathong, Nattaya Teeyapun, Suebpong Tanasanvimon, Kessarin Thanapirom, Piyawat Komolmit, Sombat Treeprasertsuk, Roongruedee Chaiteerakij, The Thai Red Cross Society, Bangkok 10330, Thailand

Nattaya Teeyapun, Suebpong Tanasanvimon, Department of Medicine, Division of Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Pisit Tangkijvanich, Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Roongruedee Chaiteerakij, Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Author contributions: Navadurong H and Chaiteerakij R designed the study; Navadurong H, Prasoppokakorn T, Siriwong N, and Phathong C contributed to data acquisition; Teeyapun N, Tanasanvimon S, Thanapirom K, Komolmit P, Tangkijvanich T, and Treeprasertsuk S recruited and managed the patients; Navadurong H, Prasoppokakorn T, and Phathong C analyzed and interpreted the data; Navadurong H, and Prasoppokakorn T drafted the manuscript; Prasoppokakorn T and Chaiteerakij R revised the manuscripts critically for important intellectual content; All the authors read and approved the final manuscript.

Institutional review board statement: The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (No.892/63).

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Roongruedee Chaiteerakij, MD, PhD, Associate Professor, Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, Khwaeng Pathum Wan, Khet Pathum Wan, Bangkok 10330, Thailand. roon.chaiteerakij@chula.md

Received: March 12, 2023
Peer-review started: March 12, 2023
First decision: April 19, 2023
Revised: July 1, 2023
Accepted: August 15, 2023
Article in press: August 15, 2023
Published online: October 15, 2023
Processing time: 211 Days and 22.7 Hours

Core Tip

Core Tip: The modified albumin-bilirubin (mALBI) grade has been shown to determine survival in hepatocellular carcinoma patients receiving locoregional and targeted therapies. This study demonstrated that mALBI can also predict survival in unresectable hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab. To improve the therapeutic outcome of atezolizumab plus bevacizumab treatment in clinical practice, mALBI assessment before initiating treatment can help in identifying suitable candidates for immunotherapy.